Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy (Q34535237)

2 August 2017

1 reference

title

Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy (English)

1 reference

2 August 2017

Ragaz J

1

1 reference

2 August 2017

publication date

1 December 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

2 August 2017

published in

1 reference

2 August 2017

volume

79

1 reference

2 August 2017

issue

1-5

1 reference

2 August 2017

page(s)

133-141

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

1 reference

7 January 2021

Novel steroidal pure antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Oestrogen receptor mutants and variants in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Mammary steroidogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Regulation of aromatase expression in human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Tamoxifen, raloxifene, and the prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

The SEEM: selective estrogen enzyme modulators in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Effects of pinostrobin on estrogen metabolism and estrogen receptor transactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900159-5

7 January 2021

10.1016/S0960-0760(01)00159-5

Identifiers

DOI

1 reference

2 August 2017

1 reference